Quantcast
The MFWire
Manage Email Alerts | Sponsorships | About MFWire | Who We Are

Subscribe to MFWire.com's News Alerts [click]

Rating:Magoon Helps Investors Bet On the Weight-Loss Med Biz Not Rated 0.0 Email Routing List Email & Route  Print Print
Tuesday, May 21, 2024

Magoon Helps Investors Bet On the Weight-Loss Med Biz

Reported by Neil Anderson, Managing Editor

A Midwestern thematic fund shop's team is rolling out a new index fund to help investors bet on companies in the GLP-1 treatment business.

Christian Magoon
Amplify Investments LLC
CEO
This morning, Christian Magoon, CEO of Amplify ETFs [profile], unveiled the launch of the Amplify Weight Loss Drug & Treatment ETF (THNR on the NYSE Arca). The new ETF is a series of Amplify ETF Trust.

THNR's inception date is today, and it comes with an expense ratio of 59 basis points. The new fund is designed to track the VettaFi Weight Loss Drug & Treatment Index.

TMX Group Limited's VettaFi LLC serves as THNR's index provider, Amplify Investments LLC serves as investment advisor, and Penserra Capital Management LLC serves as subadvisor. The new ETF's PM includes a Penserra trio: Anand Desai, senior vice president; Dustin Lewellyn, chief investment officer; and Ernesto Tong, managing director.

"The launch of THNR aligns with our mission to provide innovative thematic investment solutions across new and existing market segments," Magoon states. "We view THNR as not just an investment in high growth pharmaceuticals but as an investment in a healthier future."

THNR's other service providers include: Chapman and Cutler LLP as counsel; Cohen & Company, Ltd. as independent accounting firm; ACA's Foreside Fund Services, LLC as distributor; U.S. Bancorp Fund Services, LLC (dba U.S. Bank Global Fund Services) as administrator, fund accounting agent, and transfer agent; and U.S. Bank National Association as custodian and securities lending agent. 

Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE

0.0
 Do You Recommend This Story?



GO TO: MFWire
Return to Top
 News Archives
2024: Q4Q3Q2Q1
2023: Q4Q3Q2Q1
2022: Q4Q3Q2Q1
2021: Q4Q3Q2Q1
2020: Q4Q3Q2Q1
2019: Q4Q3Q2Q1
2018: Q4Q3Q2Q1
2017: Q4Q3Q2Q1
2016: Q4Q3Q2Q1
2015: Q4Q3Q2Q1
2014: Q4Q3Q2Q1
2013: Q4Q3Q2Q1
2012: Q4Q3Q2Q1
2011: Q4Q3Q2Q1
2010: Q4Q3Q2Q1
2009: Q4Q3Q2Q1
2008: Q4Q3Q2Q1
2007: Q4Q3Q2Q1
2006: Q4Q3Q2Q1
2005: Q4Q3Q2Q1
2004: Q4Q3Q2Q1
2003: Q4Q3Q2Q1
2002: Q4Q3Q2Q1
 Subscribe via RSS:
Raw XML
Add to My Yahoo!
follow us in feedly




©All rights reserved to InvestmentWires, Inc. 1997-2024
14 Wall Street | 20th Floor | New York, NY 10005 | P: 212-331-8968 | F: 212-331-8998
Privacy Policy :: Terms of Use